03:18 PM EST, 11/21/2025 (MT Newswires) -- Contineum Therapeutics ( CTNM ) shares were down about 10% in recent Friday trading after the company said late Thursday that its phase 2 trial of PIPE-307, in development for the treatment of patients with relapsing-remitting multiple sclerosis, failed to meet its primary and secondary efficacy goals.

The company said PIPE-307 showed an acceptable safety and tolerability profile. Contineum said it is continuing to analyze exploratory endpoints and plans to present the full dataset at a future medical meeting.

The company said it remains committed to pursuing novel therapies for patients with inflammatory and fibrotic diseases.

Price: 10.93, Change: -1.29, Percent Change: -10.56